Successful Use of Maribavir for Secondary CMV Prophylaxis in a Pediatric HSCT Patient.

IF 2.3 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-09-25 DOI:10.1002/pbc.32090

Broadman Joshua, Erin Barthelmess Goodell, Donna J Curtis, Laura McLaughlin, Amanda Strommen, Katherine T Lind

引用次数: 0

查看原文本刊更多论文

成功使用马里巴韦在儿童HSCT患者的二次巨细胞病毒预防。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.